Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will US FDA Remove Higher Strength Opioids From The Market?

Executive Summary

Advisory committee members are divided on whether agency should restrict access to higher dose opioids, but most want option kept on the table.

You may also be interested in...



How To Label Rx Drugs for Abuse And Dependence: US FDA Gives Directions For Consistency

Labeling should include signs and symptoms of withdrawal as well as abuse-deterrent properties, draft guidance states.

New Opioids May Need Comparative Effectiveness Data For Approval

Draft guidance says US FDA will consider product's benefit-risk balance relative to approved analgesics; it is particularly interested in comparative efficacy and safety data.

How To Deal With High Dose Opioids: Better Storage, Disposal And Advertising

Beyond considering removal from the market, US FDA advisory panel suggests actions agency could take to improve the safety of higher dosage strength opioids.

Topics

Related Companies

UsernamePublicRestriction

Register

PS125475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel